MXBIO key facts
- Developer of periodontal disease treatment drugs designed to offer periodontal disease treatment.
- It has raised $3.2M; the latest was Accelerator/Incubator in Jun 2025.
- Notable investors include Tech Incubator Program for Startup, Posco Investment, Shinhan Capital, KB Securities, A Ventures — 9 tracked in total.
- Status: Privately Held (backing).
- ·Watch MXBIO: the Monday email on marks, rounds and moves
MXBIO funding rounds
No funding rounds for MXBIO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
MXBIO investors
9 investors are on record for MXBIO, including Tech Incubator Program for Startup, Posco Investment, Shinhan Capital and KB Securities.
About MXBIO
Developer of periodontal disease treatment drugs designed to offer periodontal disease treatment. The company develops drugs for periodontal disease, an infection of the tissues that hold teeth in place which causes inflammation in the gums, enabling patients to be healthy.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2018
- Employees
- 13
- Website
- mx-bio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
MXBIO doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.